Overview

De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Status:
Not yet recruiting

Trial end date:
2029-06-01

Target enrollment:

Participant gender:

Summary

Immunotherapeutic approaches recently have demonstrated clinical efficacy in several cancer types, including melanoma and NSCLC. As a matter of fact, first registration trials of immune-checkpoints inhibitors (ICI) in second-line settings (pembrolizumab as well as nivolumab or atezolizumab) had stated that ICI could be continued until disease progression or not tolerable toxicity, up to 5 years. This is only for the first-line registration studies that the arbitrary maximal duration of treatment of 2 years was set up by the Companies sponsoring such trials. The aim is to study a de-escalation scheme of treatment from 2 years of immunotherapy to 6 months, in patients with controlled disease.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Intergroupe Francophone de Cancerologie Thoracique

Treatments:

Pembrolizumab
Pemetrexed